ALPMY News and Press, Astellas Pharma Inc. ADR From 03/28/24

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire - Pivotal trial found the enfo...

Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy PR Newswire Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill. , March 26, 2024 /PRNewswire/ -- Iveric Bio, An A...

Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer PR Newswire VYLOY approved in combination with chemotherapy for patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2 positive, unresectable, advanced or recurre...

Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting PR Newswire - If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastati...

2024-03-17 00:40:48 ET Summary Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024. The global multiple myeloma market size is ...

FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children PR Newswire Designation follows December 2023 FDA approval for the treatment of these serious, potentially l...

Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan PR Newswire TOKYO , March 3, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced dosing of ...

Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics PR Newswire - Innovative universal, off-the-shelf in vivo CAR-T Cell therapy - TOKYO and BOSTON , Feb. 15, 2024 /PRNewswi...

PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer PR Newswire - Priority revi...

Astellas Makes Announcement about Management Structure PR Newswire TOKYO , Feb. 6, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced the following changes to its management stru...